The following represents disclosure information provided by faculty of the educational and scientific sessions. The Committee have reviewed all presented disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
 
Karim Fizazi
 
Employment - No Relationships to Disclose
 
Leadership - No Relationships to Disclose
 
Stock and Other Ownership Interests - No Relationships to Disclose
 
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
 
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac (Inst); ESSA (Inst); Janssen Oncology; Orion Pharma GmbH; Sanofi
 
Speakers' Bureau - No Relationships to Disclose
 
Research Funding - No Relationships to Disclose
 
Patents, Royalties, Other Intellectual Property - No Relationships to Disclose
 
Expert Testimony - No Relationships to Disclose
 
Travel, Accommodations, Expenses - Amgen; Janssen
 
Other Relationship - No Relationships to Disclose
 
(OPTIONAL) Uncompensated Relationships - No Relationships to Disclose
 
(OPTIONAL) Open Payments Link - No Relationships to Disclose